© Copyright Nostre Net
Market Insights
The chronic
kidney disease market trends is expected to grow at a CAGR Of 5.40% during
the forecast period 2022-2030. Rising occurrences of chronic diseases and the
severity of kidney disease has increased the demand for an effective treatment
option for the disease. Causes of chronic diseases are often indicated by
diabetes, polycystic kidney disease, and high blood pressure among others.
Increasing R&D activities with regards
to diagnostics and treatment are expected to offer market growth opportunities
in the future. Moreover, developing economies offer a wider scope for growth
during the forecast period and are expected to affect the market positively.
Increasing prevalence of kidney diseases
and the increased number of biopsy procedures have resulted in high demand for
new diagnostic and treatment options for such chronic diseases. The global chronic
kidney disease market has become highly competitive with the increasing entry
of new market players; this is expected to stimulate growth during the forecast
period. Kidney disease symptoms are often negligible in the initial phases, and
this type of disease is widely referred to as a "silent disease" as
detection often happens when the diseases are progressed to a later stage. This
has increased the need for appropriate diagnostic measures and is driving
market growth.
Regional Analysis
The Americas and Europe are significant
regional markets which have a similar growth pattern. The growth of medical
devices, increasing awareness regarding kidney diseases and the rapid increase
in occurrences of chronic diseases is expected to drive growth in these
regions. Moreover, they display a robust demand for new treatment methods and
options. Opportunities for these markets are being driven by the increasing
emphasis on the development of new drugs. Supportive government legislature
with regards to research & development and the availability of funds for
research in these regions is expected to push the market in a forward
direction.
Asia-Pacific is another important market
due to its rapid growth. Prevalence of diseases such as diabetes and
cardiovascular diseases are driving the demand for appropriate treatment
options. The region has a rapidly improving healthcare sector which has
improved infrastructure, and a wide pool of skilled healthcare professionals.
Demand for advanced treatment technologies and other healthcare technology is
expected to provide the market with opportunities for market expansion.
Market Segmentation
MRFR's the global chronic
kidney disease market report segments on the basis of diagnosis, treatment,
indication, and end-user. By diagnosis, the market is segmented into blood
test, urine test, imaging test, and kidney biopsy. By treatment, the market is
segmented into drugs, dialysis, and kidney transplant. Drugs are further
sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers,
calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the market is segmented into
Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and
others. By end-user, The market is segmented into hospitals and clinics,
diagnostic centers, and others. Globally, the market is divided into the
Americas, Europe, Asia-Pacific & the Middle East and Africa.
Key Players
MRFRs report includes the analysis of
market players participating in the global chronic kidney diseases competitive
landscape. Top market players include Hoffman-La Roche Ltd., Abbott,
AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to
name a few.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The Wall